The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.d

Myocarditis (can be fulminant)

Can be fatal

Publications

Portolés Hernández A, Blanco Clemente M, Escribano García D, Velasco Calvo R, Núñez García B, Oteo Domínguez JF, Salas Antón C, Méndez García M, Segovia Cubero J, Domínguez F

Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report.

Cardiovascular diagnosis and therapy 2021 Aug;11;1013-1019 — 2021 Aug — 1013-1019

Inayat F, Masab M, Gupta S, Ullah W

New drugs and new toxicities: pembrolizumab-induced myocarditis.

BMJ case reports 2018 Jan 23;2018; — 2018 Jan 23

Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

Journal for immunotherapy of cancer 2015;3;11 — 2015 — 11